Nom du chef de service VITTECOQ Daniel Mail daniel.vittecoq@pbr.aphp.fr
Thématique 1 : Recherche et développement des antirétroviraux
Thématique 2 : Recherche et développement dans l’hépatite C
Mots clés : co-infection VIH/VHC - transplantation hépatique
Encadrement de master ou thèse oui
Thématique 3 : Rôle des peptides antimicrobiens dans l’immunité vésicale et digestive
Mots clés : immunité innée, peptides antimicrobiens
Responsable scientifique : B Wyplosz Mail benjamin.wyplosz@pbr.aphp.fr
Encadrement de master ou thèse oui
1. Wyplosz B, Carlotti A, Escaut L, Vignier N, Guettier C, Agbalika F, Vittecoq D, Dupin N. Initial human herpesvirus-8 rash and multicentric Castleman disease. Clin Infect Dis. 2008 Sep 1;47(5):684-8.
2. Duclos-Vallée JC, Féray C, Sebagh M, Teicher E, Roque-Afonso AM, Roche B, Azoulay D, Adam R, Bismuth H, Castaing D, Vittecoq D, Samuel D; THEVIC Study Group. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2008 Feb;47(2):407-17.
3. Teicher E, Vincent I, Bonhomme-Faivre L, Abbara C, Barrail A, Boissonnas A, Duclos-Vallée JC, Taburet AM, Samuel D, Vittecoq D. Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. Clin Pharmacokinet. 2007;46(11):941-52.
4. Couzigou C, Daudon M, Meynard JL, Borsa-Lebas F, Higueret D, Escaut L, Zucman D, Liotier JY, Quencez JL, Asselah K, May T, Neau D, Vittecoq D. Urolithiasis in HIV-positive patients treated with atazanavir. Clin Infect Dis. 2007 Oct 15;45(8):e105-8.
5. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, Gonzalez CJ, Chen J, Harvey CM, Isaacs RD; Protocol 005 Team. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet. 2007 Apr 14;369(9569):1261-9.
6. Monsuez JJ, Escaut L, Teicher E, Charniot JC, Vittecoq D. Cytokines in HIV-associated cardiomyopathy. Int J Cardiol. 2007 Aug 21;120(2):150-7.
7. Sacre K, Carcelain G, Cassoux N, Fillet AM, Costagliola D, Vittecoq D, Salmon D, Amoura Z, Katlama C, Autran B. Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease. J Exp Med. 2005 Jun 20;201(12):1999-2010.
8. Tubiana R, Carcelain G, Vray M, Gourlain K, Dalban C, Chermak A, Rabian C, Vittecoq D, Simon A, Bouvet E, El Habib R, Costagliola D, Calvez V, Autran B, Katlama C; for the Vacciter Study group. Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094). Vaccine. 2005 Jul 29;23(34):4292-301.
9. Duclos-Vallée JC, Vittecoq D, Teicher E, Feray C, Roque-Afonso AM, Lombès A, Jardel C, Gigou M, Dussaix E, Sebagh M, Guettier C, Azoulay D, Adam R, Ichaï P, Saliba F, Roche B, Castaing D, Bismuth H, Samuel D. Hepatitis C virus viral recurrence and liver mitochondrial damage after liver transplantation in HIV-HCV co-infected patients. J Hepatol. 2005 Mar;42(3):341-9.
10. Izzedine H, Isnard-Bagnis C, Hulot JS, Vittecoq D, Cheng A, Jais CK, Launay-Vacher V, Deray G. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS. 2004 Apr 30;18(7):1074-6.
